Objective The P2X7 receptor (P2X7R) is a key regulatory element in the neuroinflammatory cascade that provides a promising target for imaging neuroinflammation. GSK1482160, a P2X7R modulator with nanomolar binding affinity and high selectivity, has been successfully radiolabeled and utilized for imaging P2X7 levels in a mouse model of lipopolysaccharide-induced systemic inflammation. In the current study, we further characterized its binding profile and determined whether [
11 C] GSK1482160 can detect changes in P2X7R expression in a rodent model of multiple sclerosis.
Methods [ 11 C]GSK1482160 was synthesized with high specific activity and high radiochemical purity. Radioligand saturation and competition binding assays were performed for [ 11 C]GSK1482160 using HEK293-hP2X7R living cells. Micro-PET studies were carried out in nonhuman primates. In vitro autoradiography and immunohistochemistry studies were then carried out to evaluate tracer uptake and P2X7 expression in experimental autoimmune encephalomyelitis (EAE) rat lumbar spinal cord at EAE-peak and EAE-remitting stages compared with sham rats. 
Results

Introduction
Neuroinflammation is a common characteristic of numerous neurodegenerative diseases, including multiple sclerosis (MS) [1] . Substantial data indicate that the P2X7 receptor (P2X7R) plays a key regulatory role in the inflammasome molecular complex [2] . Under normal physiological conditions, P2X7R is a 'silent receptor' because of a low extracellular ATP concentration and the low affinity of ATP to P2X7R [3] . In contrast, inflammatory conditions significantly increase extracellular ATP concentration with subsequent upregulation of P2X7R. This stimulates post-translational modification and subsequent release of proinflammatory cytokines, which could initiate the neuroinflammatory cascade [3] . P2X7R is highly expressed in activated microglia [4] , which could act as a potential target for PET imaging of neuroinflammation and for therapeutic intervention. P2X7R knockout mice showed a suppressed inflammatory response to a systemic injection of ATP and lipopolysaccharides (LPS) [5] . Moreover, pharmacological blockade of P2X7R produces an antineuroinflammatory effect in animal models of seizure [6] , spinal cord injury [7] , subarachnoid hemorrhage [8] , Alzheimer disease [9] , and multiple sclerosis [10] . Concordantly, a P2X7R-specific PET radioligand would enable an in vitro assessment of central nervous system P2X7R expressions that could be potentially useful for monitoring disease severity and therapeutic response to anti-inflammatory drugs. and high selectivity. Recently, the carbon-11 labeling of [ 11 C]GSK1482160 was reported by Dr. Bennacef's group [11] and Dr. Zheng's group [12] , and been applied for imaging the P2X7 level in a mouse model of LPS-induced systemic inflammation [13] . In the current study, the potential of [ 3 OTf was bubbled into a solution of the reaction mixture in a 5 ml vial (1.0-2 mg precursor and 1 mg NaH in 0.2 ml CH 3 CN). The reaction vial was sealed and heated at 80°C for 5 min. The reaction was quenched by adding 1.7 ml of mobilephase solution. Then, the diluted radioactive mixture was injected into a reverse-phase semipreparative HPLC column (9.6 × 250 mm, 5 μm) with a 2 ml injection loop for purification using the mobile phase of acetonitrile/0.1 mol/l aqueous ammonium formate buffer (35/65, v/v, pH = 4.5), with a UV wavelength of 254 nm and a flow rate of 4.0 ml/min. Under these conditions, [ 11 C]GSK1482160 was collected between 13 and 15 min in a flask of sterile water (50 ml). The diluted aqueous solution was passed through C18 Sep-Pak Plus (WAT020515; Waters, Milford, Massachusetts, USA) and washed with sterile water (20 ml). The radioactive product was eluted using EtOH (0.6 ml), followed by 0.9% of saline (5.4 ml). After sterile filtration into a glass dose vial, the product was ready for quality control analysis and animal study. For the quality control, an aliquot of the final dose sample was authenticated with a cold standard solution of compound GSK1482160 using an analytical HPLC system that included a reverse-phase Agilent ZORBAX SB-C18 column (4.6 × 250 mm, 5 μm). Using the mobile phase of 47% acetonitrile in 0.1 mol/l ammonium formate buffer (pH = 4.5), flow rate 1.0 ml/min; UV wavelength 254 nm, the retention time of the radiotracer [ 11 C]GSK1482160 was ∼ 5.1 min.
Radioligand binding assay HEK293-hP2X7R cell culture Human embryonic kidney 293 cells stably transfected with the human P2X7R (HEK293-hP2X7R) were maintained in Dulbecco's modified Eagle's medium supplemented with 10% fetal calf serum, antibiotics (50 U/ml penicillin and 50 μg/ml streptomycin), and 800 µg/ml Geneticin (Invitrogen Inc., Carlsbad, California, USA). Cells were grown in a 75 ml cell culture flask in a humidified atmosphere of 5% CO 2 at 37°C. Confluent HEK293-hP2X7R cells were washed twice with cold PBS, then Western blots assessed the protein level and FACS confirmed the expression of the P2X7R (Fig. 1a and b) following published protocols [15, 16] .
Radioligand saturation binding assay
For saturation binding measures, 2.5 × 10 5 human HEK293-hP2X7R cells per well were placed in a 96-well polylysine-coated microplate (Bioworld Inc., Dublin, Ohio, USA) overnight. Culture medium was removed on the second day and cells were washed three times with 250 µl/well ice-cold assay buffer, which was 50 mmol/l Tris-HCl pH 7.4 with 0.1% BSA. Then, 90 µl/well of assay buffer with serially diluted [ 11 C]GSK1482160 and 10 µl of assay buffer only (for total binding) or 10 µl of assay buffer with a 100 µmol/l final concentration of cold GSK1482160 were added (for nonspecific binding). The final concentration of [ 11 C]GSK1482160 was in the range of 0.2-400 nmol/l, calculated on the basis of the radioactivity concentration and the specific activity. Triplicate wells were prepared for each concentration in the assay. Wells were incubated for 1 h on ice in a shaking water bath. Binding activities were terminated by rapid washing of the plate five times with 200 µl/well of ice-cold assay buffer. After the last wash, 150 µl/well of 0.5% Sodium dodecyl sulfate was added. After 1-2 min, clean cell lysate from the 96-well microplate were transferred to a scintillation vial and 2 ml of Bio-Safe II complete counting cocktail (Research Products Inc., Mount Prospect, Illinois, USA) was added to each sample. Samples were counted on a Wallac 1450 MicroBeta TriLux liquid scintillation counter (PerkinElmer, Boston, Massachusetts, USA). Each sample was counted for 30 s at the energy window of 5-1024 keV and radioactivity of all samples (cpm) was decay corrected (half-life of 20.3 min) to the point when the specific activity of [ 11 C] GSK1482160 was determined. Normally, a total of ∼ 56 MBq of [
11 C]GSK1482160 is needed to obtain reasonable counting statistics and the entire experiment, including washing the plate, transferring samples, and counting samples, was completed in less than 1 h. Data analysis was carried out using GraphPad Prism (GraphPad Software Inc., San Diego, California, USA). The specifically bound counts (cpm) from the saturation binding experiments were calculated based on the total binding subtraction of the nonspecific binding, and then concentration-effect data were curve-fit to a one-site binding (hyperbola) equation to derive the dissociation constant of the radioligand (K d ) and the number of binding sites (B max , cpm/1 × 10 6 cells).
Radioligand competition binding assay
In radioligand competition binding studies, 2.5 × 10 5 HEK293-hP2X7R cells/well were placed in a 96-well polylysine-coated microplate overnight. Culture medium was removed on the second day and cells were washed three times with 250 µl/well ice-cold assay buffer. Then, 80 µl/well of assay buffer, 10 µl of assay buffer with serial diluted cold GSK1482160 (final concentration in the range of 0.1 nmol/l to 3 µmol/l), and 10 µl of assay buffer with a fixed concentration of [ 11 C]GSK1482160 (41 nmol/ l on the basis of decay corrected radioactivity concentration and specific activity) were added. Duplicate wells were prepared for each concentration in the assay. The rest of the procedure was the same as the saturation binding. The specific binding (cpm) was expressed as a percentage of the maximal binding observed in the absence of the test compound, and then the concentration-effect data were curve-fit to a three-parameter inhibitor-effect equation to derive the potency (IC 50 ) of the test compound. The equilibrium dissociation constant (K i ) of the test compound was calculated using the Cheng-Prusoff equation:
where L is the [ 11 C]GSK1482160 concentration used and K d was set to the mean value from saturation assays. [17] [18] [19] . Core temperature was maintained at about 37°C with a heated water blanket. The head was secured in a head holder with the brain in the center of the field of view. Subsequently, a 2 h dynamic emission scan was acquired after the administration of 290 -410 MBq of [ 11 C] GSK1482160 through the venous catheter.
PET scans were collected from 0 to 120 min at the following time points: 3 × 1, 4 × 2, 3 × 3, and 20 × 5 min. Emission data were corrected for dead time, scatter, and attenuation and then reconstructed to a final resolution of 2.0 mm full-width half-maximum in all three dimensions at the center of the field of view. PET and MRI images were co-registered using an automated image registration program [20] . For quantitative analyses, a threedimensional region of interest (the global brain) was identified on the MRI and transformed to the reconstructed PET images to obtain time-activity curves. Activity measures were standardized to body weight and the dose of radioactivity injected to yield the standardized uptake value (SUV).
Induction of EAE in female Lewis rats and tissue preparation
All rodent experiments were also conducted in compliance with the Guidelines for the Care and Use of Research Animals under protocols approved by Washington University's Animal Studies Committee. The EAE rat model was induced according to our published procedure [21] . In brief, female Lewis rats (Charles River Laboratories Inc., Wilmington, Massachusetts, USA), weighing 100-125 g, were divided randomly into three groups: sham group (n = 6), EAE-P (peak) group (n = 7), referring to 12-14 days postimmunization corresponding to the highest disability score (4.0-5.0) in the acute phase of the disease, and the EAE-R (autoremitting) group (n = 4), which was about 4 weeks after immunization when the symptoms had disappeared completely (score 0). Before each immunization, a myelin basic protein (MBP) emulsion was freshly prepared using an MBP fragment (MBP68-86; AnaSpec Inc., San Jose, California, USA). Emulsification was performed by mixing an MBP68-86 solution (0.5 mg/ml in PBS) with an equal volume of complete Freund's adjuvant (CFA) containing 1 mg/ml heat-inactivated Mycobacterium tuberculosis H37Ra (Difco Laboratories, Detroit, Michigan, USA). Similarly, a control emulsion was freshly prepared by emulsifying equal volumes of PBS and CFA containing 1 mg/ml heat-inactivated M. tuberculosis.
P2X7R radioligand for neuroinflammation
Immunization of rats was performed under anesthesia (2-3% isoflurane in O 2 ) by injecting 200 μl of emulsion, divided equally between the hind footpads. Control rats were injected with an identical volume of a PBS/CFA emulsion.
Subsequent to each immunization, animal weight and neurological deficits were monitored daily. The following scoring system was used to grade neurological impairment: 0, no symptoms; 1, flaccid tail; 2, hindlimb weakness; 3, paraparesis; 3.5, unilateral hindlimb paralysis; 4, bilateral hindlimb paralysis; and 5, bilateral hindlimb paralysis and incontinence. Animals from the three groups were euthanized separately; the lumbar regions of spinal cords that showed the most severe lesion were used for further tissue processing. Spinal cords were rapidly dissected on ice. Isolated tissues were then dissected and cut in half. One half of the lumbar spinal cord was fixed in 10% formalin and processed for immunohistochemical (IHC) studies. The other half was snap frozen and cut into 20 μm thick slices for in-vitro autoradiographic studies.
Autoradiography studies of EAE rat spinal cord slices
To assess the difference in tracer uptake in rat spinal cord, 20 μm slices from EAE and sham rats were incubated with 2.8 MBq/ml [ 11 C]GSK1482160 at room temperature for 30 min following a 15 min preincubation in 50 mmol/l Tris-HCl buffer (pH 7.4). After this incubation, sections were washed two times in assay buffer at 4°C and rinsed once in distilled water at 4°C to remove buffer salts. Then, the slides were air-dried and exposed to the storage phosphor screen in an imaging cassette for 2-4 h in − 20°C in the dark. The distribution of radioactivity was visualized using a Fuji Bio-Imaging Analyzer FLA-7000 (Fuji Photo Film, Tokyo, Japan). Photostimulated luminescence was quantified using Multi Gauge v3.0 software (Fuji Photo Film). Data were background-corrected and expressed as photostimulated luminescence signals per square millimeter (PSL/mm 2 ).
Immunohistochemical staining of EAE rat spinal cord slices
To investigate the change in P2X7R expression and microglia activation during the EAE progression, 5 μm thick fixed slices from rat lumbar spinal cords were used for IHC studies. Slides were deparaffinized in xylene and rehydrated through a graded alcohol series. Endogenous peroxidase activity was quenched with 3% H 2 O 2 in methanol for 10 min following antigen retrieval. After blocking in room temperature for 1 h, slides were incubated with the primary antibody overnight at 4°C. The primary antibodies used for this study included a rabbit anti-rat P2X7R antibody (Abcam, Cambridge, Massachusetts, USA) that was diluted (1 : 400 ratio) in PBS and a mouse anti-rat Iba-1 antibody (Millipore, Billerica, Massachusetts, USA) that was diluted (1 : 300 ratio) in PBS. Slides were then washed in PBS and detected using an anti-rabbit or an anti-mouse HRP-DAB staining kit (R&D Systems, Minneapolis, Minnesota, USA) according to the manufacturer's instructions. Negative controls were carried out without adding the primary antibody. A Nikon E600 microscope (Nikon Corporation, Tokyo, Japan) coupled with a charge-coupled device camera was used to obtain all photomicrographs.
Images were captured using ACT-1 software (Nikon Corporation). Eight representative pictures in white matter and six in gray matter ( Supplementary Fig. S1 , Supplemental digital content 1, http://links.lww.com/NMC/ A111) were taken from rat lumbar spinal cord traverse sections with a × 20 NIKON objective. Image J 1.49 V (NIH, Bethesda, Maryland, USA; https://imagej.nih.gov/ij/) was used for image processing. For quantifications, the total positive number of cells was counted by Image J for P2X7R and Iba-1, and the positive cell density (cells/100 µm 2 ) was used for comparison. Data are presented as mean SD. For statistical comparison, the unpaired one-way analysis of variance and post-hoc tests Bonferroni multiple-comparison test were applied using Prism 6.01 (GraphPad Prism Software, La Jolla, California, USA) and P less than 0.05 was considered statistically significant.
Results
Radiochemistry
[ 11 C]GSK1482160 was obtained in high specific activity 260-360 GBq/µmol (decay corrected to end of bombardment), with a radiochemical yield of 30-40% (end of bombardment) and radiochemical purity of more than 99% (n > 10).
Radioligand binding assay [ 11 C]GSK1482160 binds to the recombinant human P2X7R with high affinity. As shown in Fig. 1 , the measured K d was 5.09 0.98 nmol/l on the basis of the saturation binding studies. The saturation binding data indicated that specific binding represented~40% of total binding. The cell competition assay showed that the IC 50 was 12.2 2.5 nmol/l and the calculated K i value was 2.63 0.6 nmol/l. These results are consistent with data from a previous fluorescence screening assay and a radioligand assay reported in other studies [13, 25] . The specific binding data fit a straight line in the Scatchard plot, suggesting that the one-site binding model is a good model for [ (Fig. 2a) . The tissue time-activity curves indicated that the tracer uptake in the total brain reached the maximum SUV value (∼2.45) at ∼ 70 min after injection and remained stable till the end of the 2-h scan, shown in Fig. 2b . In addition, the variation in SUV values between two animals (SD) was small, indicating good reproducibility of PET measures using [ To validate the application of [ 11 C]GSK1482160 in detecting and monitoring the change in P2X7R levels under neuroinflammatory conditions, in-vitro autoradiographic studies were carried out using a rodent EAE model. EAE-P rats, which were in the acute phase of the disease (12-14 days after immunization), had the most severe symptoms (score: 4.0-5.0), and neuroinflammation. EAE-remitting (EAE-R) rats, which were in the auto-recovery stage (∼4 weeks after immunization), showed no obvious symptoms (score 0). Autoradiographic study showed more than four-fold higher tracer uptake in EAE-P rat lumbar spinal cord than sham (277.74 79.74 vs. 66.37 1.48 PSL/mm 2 , n = 2-3, Fig. 3 ). The tracer uptake in EAE-R tissues was decreased by half (149.00 54.14 PSL/mm 2 , n = 3, Fig. 3 ) compared with EAE-P, but still about two-fold higher than sham. The ratio of EAE-P : EAE-R : sham = 4.18 : 2.25 : 1.
P2X7R expression in EAE rat lumbar spinal cord
To further confirm the expression of P2X7R protein in rat spinal cord during EAE progression, IHC staining was performed. P2X7R-positive cells were observed in lumbar spinal cord from all three groups (Fig. 4a) . The number of P2X7R-positive cells increased significantly in both EAE-P and EAE-R groups, and was especially higher in the EAE-P group, compared with sham ( Fig. 4b  and c) . In white matter, P2X7R-positive cells in the EAE-P group (n = 7) were 10.80 1.91/100 µm 2 , which was three times higher than that in the sham group (3.34 0.85/100 µm 2 , n = 6, P < 0.01). The numbers in the EAE-R group (n = 4) reverted to 7.12 0.10/100 µm 2 ( Fig. 4a and b) , which were lower than the EAE-P group (P < 0.05), but still higher than the sham group (P < 0.05). The ratio of EAE-P : EAE-R : sham in white matter = 3.02 : 2.13 : 1. A similar trend was found in gray matter. The number of P2X7R-positive cells in gray matter of the EAE-P group was 6.47 0.92/100 µm 2 , which was two times higher than the sham group (2.84 0.75/100 µm 2 , P < 0.01) and higher than the EAE-R group (4.50 0.24/100 µm 2 , Fig. 4a and c) . The ratio of EAE-P : EAE-R : sham in gray matter = 2.28 : 1.58 : 1. Copyright r 2017 Wolters Kluwer Health, Inc. All rights reserved.
Microglial activation in EAE rat lumbar spinal cord
To explore microglial activation in EAE rat spinal cord, IHC staining with a specific antibody for microglia/macrophage (anti-Iba-1 antibody) was applied. Iba-1-positive cells were detected throughout white and gray matter in the lumbar spinal cord of all three groups (Fig. 5a) . Although a few Iba-1-positive cells were observed in the sham group, which reflected the baseline level of microglia at rest, the number of Iba-1-positive cells increased significantly in both the EAE-P and the EAE-R group, especially in the EAE-P group (Fig. 5b and c) . A similar distribution trend of Iba-1-positive cells was found within both white matter and gray matter, which was consistent with a previous report [21] . In white matter, the number of Iba-1-positive cells reached the maximum (9.76 1.19/ 100 µm 2 ) in the EAE-P group and then decreased to 6.13 1.30/100 µm 2 in the EAE-R group. Both of these values were much higher than those in the sham group (0.51 0.06/100 µm 2 , P < 0.01 for EAE-P vs. sham, P < 0.01 for EAE-R vs. sham); the positive cells of the EAE-P group were also higher than those in the EAE-R group (P < 0.05) (Fig. 5a and b) . The Iba-1-positive cells in gray matter showed a similar trend (Fig. 5c ). In the sham group, the positive cell number was 0.58 0.21/100 µm 2 and the number reached 8.84 1.07/100 µm 2 in the EAE-P group. The positive cell number in the EAE-R group also was higher (5.38 0.93/100 µm 2 ) than that in the sham group (P < 0.01), whereas the positive cell number in the EAE-P group was higher than that in the EAE-R group (P < 0.05).
Discussion
Advances in molecular imaging of neuroinflammation in the past decade have improved our understanding of the neuroinflammatory mechanism in neurodegenerative diseases. Yet, current PET imaging of neuroinflammation remains in its infancy. PET radioligands targeting translocator protein 18 kDa (TSPO) have been used widely in preclinical and clinical assessments of microglia activation. However, a genetic polymorphism regulates the expression of the TSPO protein, resulting in marked differences in the normal binding affinity of TSPO radiotracers in the human brain [22] . Thus, genetic screening of individual patients must be performed to interpret these PET measures. New PET radioligands of neuroinflammation that are not dependent on such polymorphism are critically needed for human studies.
P2X7R orchestrates neuroinflammation and offers a promising target for radioligand development for neuroinflammation. To date, only a few P2X7R radioligands have been reported in preclinical studies, including [ [23] . Radiotracer [ 11 C]JNJ54173717 has been evaluated in a rat model expressing human P2X7Rs and healthy nonhuman primates for in vivo visualization of P2X7Rs in the brain [24] . [ 11 C]JNJ54173717 has high brain uptake in the first hour after tracer injection, suggesting its suitability as a PET radiotracer to reflect P2X7R expression. However, the radioactivity concentration of [ 11 C]JNJ54173717 continued to increase in the NHP brain after 75 min after the tracer injection, which may reflect accumulation of radioactive metabolites [24] .
In this study, we characterized in vitro in cell membrane preparations and the in vivo behavior of [ blood-brain barrier penetration as well as a homogeneous distribution in NHP brain. Our finding is consistent with previous reports that also indicated a widespread distribution of P2X7 in rodent and NHP brains [13, 24, 26] , although one autoradiography study using [ 3 H]-A-804598 showed heterogeneity of binding site intensity in rat brain [27] . In addition, the homogeneous distribution of [ 11 C]GSK1482160 in the brain would not impact its application in detecting the increase in P2X7 expression under neuroinflammatory conditions, especially those with focal inflammatory lesions such as trauma and infection. Compared with the in-vivo kinetics of [ 11 C] JNJ54173717, which reaches the peak fast and then washes out quickly from the brain [4] , [ 11 C]GSK1482160 has a relatively high retention in the brain over the 2 h PET scan period. A previous study suggested that [ 11 C] GSK1482160 is metabolically stable and metabolite correction will have minimal impact on kinetics [2] . Therefore, the high brain retention of [ 11 C]GSK1482160 could enable stable and reproducible PET measures at a relatively late time point after tracer injection. Also, the relatively slow washout kinetics of [ 11 C]GSK1482160 may provide better imaging for static scan acquisition.
Encouraged by both in vitro pharmacologic characterization of [ 11 C]GSK1482160 and micro-PET study in the brain of nonhuman primates, we measured the change in P2X7R expression in reponse to neuroinflammation. Neuroinflammation plays a key role in the demyelinating pathogenesis of MS. The rat EAE model of MS includes acute severe neuroinflammation in lumbar spinal cord, with modest demylination, and has been used in our laboratory for the evaluation of radioligands targeting neuroinflammation [21] . Noteably, [ 11 C]GSK1482160 showed 100 times lower binding affinity for the rodent P2X7R versus the human P2X7R (316 vs. 3.16 nmol/l) [28] . As a result, micro-PET imaging of [ 11 C]GSK1482160 in rat spinal cord showed an approximately 14% increase in tracer uptake (in terms of SUV) in EAE rats compared with sham rats ( Supplementary Fig. S2 , Supplemental digital content 2, http://links.lww.com/NMC/A111). However, the relatively low tracer uptake in the rat spinal cord that may have been caused by low binding affinity (∼316 nmol/l) of [ 11 C] GSK1482160 to rodent tissues resulted in a poor image resolution, and thus tempered further investigation of micro-PET studies in this EAE rat model. Therefore, we used in-vitro autoradiography to assess the change in P2X7R expression in rat lumbar spinal cord during the course of this EAE rodent model.
In vitro autoradiography using [
11 C]GSK1482160 showed a strong correlation between tracer uptake and disease progression. EAE-P rat tissues have the highest tracer accumulation, followed by tissues from the EAE-R group and the sham rats. This rank order matched the EAE score across these three groups. The tracer concentration used in the autoradiographic study (∼400 nmol/l) was relatively high and was close to the reported binding affinity of GSK1482160 in rat P2X7Rs (316 nmol/l) [25] . We also directly examined P2X7R expression and the related inflammatory response in EAE rat lumbar spinal cord using immunohistochemistry. The elevated expression of P2X7R in EAE rat brains has been reported previously [29] , but the correlation of P2X7R expression and microglial activation remains obscure. In MS patients and EAE rodent models, microglia show uncontrolled activation and produce proinflammatory mediators to recruit inflammatory cells such as T cells [30, 31] . Moreover, it can also directly release a variety of cytotoxic substances and cause cellular damage, including interleukin-1β [32] . The P2X7R plays a vital role in microgliamadiated interleukin-1β processing and release through the membrane receptors, which promotes inflammatory damage in the central nervous sysytem [33] [34] [35] [36] [37] . We detected enhanced P2X7R expression and microglia activation in EAE-P rat tissues. The P2X7R level in EAE spinal cord also remained upregulated during the remitting stage, which is in agreement with the autoradiographic findings. Our autoradiographic and immunohistological data showed that the tracer uptake of [ 11 C]GSK1482160 in EAE rat lumbar spinal cord correlated with the P2X7R protein level, microglial activation, and disease severity.
Conclusion
[ 11 C]GSK1482160 has a high binding affinity to hP2X7R, crosses the blood-brain barrier, and homogeneously distributes in the NHP brain. In vitro autoradiography with [ 11 C]GSK1482160 enabled successful monitoring of the change in P2X7R expression in lumbar spinal cord in an EAE rat model; the tracer uptake was strongly correlated with both microglia activation and disease severity. Therefore, NHP models of neuroinflamation are warranted to test the feasibility of micro-PET with [ 11 C] GSK1482160 in imaging and monitoring neuroinflammation. Considering the higher binding potency of in human brain tissues, [ 11 C]GSK1482160 has high potential for assessing neuroinflammatory responses in MS patients.
